期刊文献+

人凝血酶原复合物中凝血因子活性测定的影响因素研究 被引量:4

Study on the influening factors of four coagulation factors' altivity detemination in human prothrombin complex concentrates
下载PDF
导出
摘要 目的探讨几种因素对人凝血酶原复合物(prothrombin complex concentrates,PCC)中凝血因子活性测定的影响。方法参照《中国药典》(2010版),采用不同样品前处理、不同稀释剂、不同盐离子浓度制品、不同测定标准品及不同厂家试剂分析其对PCC中凝血因子II、VII、IX、X活性测定结果的影响。结果 PCC加入硫酸鱼精蛋白,凝血因子II、VII、X活性降低,凝血因子IX活性升高;样品37℃温浴15min与否,4种因子活性测定统计显示无显著差异。乏浆、生理盐水、蒸馏水及配套稀释液稀释对4种因子活性测定结果影响统计显示有显著差异(P<0.05);含1mol/L氯化钠的制品,凝血因子II、X活性测定结果显著低于含0.25mol/L氯化钠制品(P<0.05),而凝血因子VII、IX无统计学差异。不同标准品,测定的因子活性均不同。不同厂家试剂对4种凝血因子测定结果统计显示有显著差异(P=0.00)。结论 PCC前处理条件、测定稀释剂、制品所含的盐离子浓度、测定标准品及不同厂家的试剂均影响其凝血因子的活性测定,在检测过程中应予重视。 Objective To study the inlfuence factors on detection of activity of four coagulation factors in prothrombin complex concentrates (PCC) by several factors. Methods Using Pharmacopoeia of the People’s Republic of China (2010) as reference, the activity of four coagulation factors in PCC were investigated by choosing different pre-treatments, different diluents, different salt concentration, different standard human plasma and different company reagents. Results The activity of FII, FVII, FX were decreased and FIX was increased in the condition of adding protamine sulfate, and there were no differences of four coagulation factors whether warm bath in 37 for 15 min or not. However, the differences of four coagulation factors were significant by using deficient plasma, saline, distilled water and commercial dilution buffer(P<0.05). The activity of coagulation factor II, X in 1 mol/L salt concentration of PCC were significantly lower than in 0.25 mol/L(P<0.05), while coagulation factor VII, IX were not. The activity of FII, FVII, FIX, and FX were different by using different standard human plasma to make standard curve. The activity of four coagulation factors existed significant difference(P=0.00) by using SIEMENS company reagents and domestic reagents. Conclusion Choosing different pre-treatments, different dilution buffers, salt concentration, standard human plasma and commercial kits will inlfuence the detection result of coagulation factors.
出处 《中国生化药物杂志》 CAS 北大核心 2014年第2期17-19,共3页 Chinese Journal of Biochemical Pharmaceutics
基金 国家高技术研究发展计划("863"计划)项目(2012AA021903-3)
关键词 凝血酶原复合物 硫酸鱼精蛋白 稀释剂 盐离子浓度 标准品 prothrombin complex concentrates protamine sulfate dilution buffer salt concentration standard human plasma
  • 相关文献

参考文献10

二级参考文献91

  • 1黄金明,刁武萍,祝慈芳,吴玮,陈延,韩剑秋.凝血酶原复合物病毒灭活的研究[J].中国生物制品学杂志,1995,8(3):101-104. 被引量:6
  • 2赵彦鼎.人血源凝血因子Ⅸ纯化研究概况[J].中国输血杂志,2006,19(5):412-415. 被引量:5
  • 3Chandra S, Brummelhuis H G. Prothrombin complex concentrates for clinical use [ J ]. Vox Sang, 1981,41 (5-6) : 257-273. 被引量:1
  • 4Burnouf T. Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates[J]. Biologicals, 1992,20(2) :91-100. 被引量:1
  • 5国家药典委员会.中国药典2005年版:三部[S].北京:化学工业出版社,2005:193-194. 被引量:1
  • 6Hoffer L, Schwinn H, Josi C D. Production of highly purified clotting factor Ⅸ by a combination of different chromatographic methods [ J ]. J Chromatogr A, 1999,844(1-2) : 119-128. 被引量:1
  • 7Seitz R, Dodt J. Virus safety of prothrombin complex concentrates and factorⅨ concentrates[J] .Thromb Res,1999,95(4 Suppl 1) :S19-S23. 被引量:1
  • 8Surgenor DM, Melin M, Steele BB, et al. Preparation of barium sulphate eluate of plasma for physiological studies in humans[ J]. Vox Sang ,1959, 4( 1 ) : 71-72 被引量:1
  • 9Barrowcliffe TW, Stableforth P, Dormandy KM. Small scale preparation and clinical use of factor IX prothrombin complex[ J]. Vox Sang,1973, 25(5) : 426-441 被引量:1
  • 10Hoag MS, Johnson FF, Robinson JA, et al. Treatment of hemophilia B with a new clotting -factor concentrate [ j ]. New Engl J Med,1969, 280(11 ): 581-586 被引量:1

共引文献32

同被引文献19

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部